Cargando…

Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways

Background and Purpose: Hydrogen (H(2)) has been shown to have a strong antioxidant effect on preventing oxidative stress-related diseases. The goal of the present study is to determine the pharmacodynamics of H(2) in a model of isoproterenol (ISO)-induced cardiac hypertrophy. Methods: Mice (C57BL/6...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaxing, Xu, Jingting, Long, Zhiyuan, Wang, Chen, Wang, Ling, Sun, Peng, Li, Ping, Wang, Tinghuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081383/
https://www.ncbi.nlm.nih.gov/pubmed/27833552
http://dx.doi.org/10.3389/fphar.2016.00392
_version_ 1782462880182960128
author Zhang, Yaxing
Xu, Jingting
Long, Zhiyuan
Wang, Chen
Wang, Ling
Sun, Peng
Li, Ping
Wang, Tinghuai
author_facet Zhang, Yaxing
Xu, Jingting
Long, Zhiyuan
Wang, Chen
Wang, Ling
Sun, Peng
Li, Ping
Wang, Tinghuai
author_sort Zhang, Yaxing
collection PubMed
description Background and Purpose: Hydrogen (H(2)) has been shown to have a strong antioxidant effect on preventing oxidative stress-related diseases. The goal of the present study is to determine the pharmacodynamics of H(2) in a model of isoproterenol (ISO)-induced cardiac hypertrophy. Methods: Mice (C57BL/6J; 8–10 weeks of age) were randomly assigned to four groups: Control group (n = 10), ISO group (n = 12), ISO plus H(2) group (n = 12), and H(2) group (n = 12). Mice received H(2) (1 ml/100g/day, intraperitoneal injection) for 7 days before ISO (0.5 mg/100g/day, subcutaneous injection) infusion, and then received ISO with or without H(2) for another 7 days. Then, cardiac function was evaluated by echocardiography. Cardiac hypertrophy was reflected by heart weight/body weight, gross morphology of hearts, and heart sections stained with hematoxylin and eosin, and relative atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) mRNA levels. Cardiac reactive oxygen species (ROS), 3-nitrotyrosine and p67 (phox) levels were analyzed by dihydroethidium staining, immunohistochemistry and Western blotting, respectively. For in vitro study, H9c2 cardiomyocytes were pretreated with H(2)-rich medium for 30 min, and then treated with ISO (10 μM) for the indicated time. The medium and ISO were re-changed every 24 h. Cardiomyocyte surface areas, relative ANP and BNP mRNA levels, the expression of 3-nitrotyrosine, and the dissipation of mitochondrial membrane potential (MMP) were examined. Moreover, the expression of extracellular signal-regulated kinase1/2 (ERK1/2), p-ERK1/2, p38, p-p38, c-Jun NH2-terminal kinase (JNK), and p-JNK were measured by Western blotting both in vivo and in vitro. Results: Intraperitoneal injection of H(2) prevented cardiac hypertrophy and improved cardiac function in ISO-infused mice. H(2)-rich medium blocked ISO-mediated cardiomyocytes hypertrophy in vitro. H(2) blocked the excessive expression of NADPH oxidase and the accumulation of ROS, attenuated the decrease of MMP, and inhibited ROS-sensitive ERK1/2, p38, and JNK signaling pathways. Conclusion: H(2) inhibits ISO-induced cardiac/cardiomyocytes hypertrophy both in vivo and in vitro, and improves the impaired left ventricular function. H(2) exerts its protective effects partially through blocking ROS-sensitive ERK1/2, p38, and JNK signaling pathways.
format Online
Article
Text
id pubmed-5081383
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-50813832016-11-10 Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways Zhang, Yaxing Xu, Jingting Long, Zhiyuan Wang, Chen Wang, Ling Sun, Peng Li, Ping Wang, Tinghuai Front Pharmacol Pharmacology Background and Purpose: Hydrogen (H(2)) has been shown to have a strong antioxidant effect on preventing oxidative stress-related diseases. The goal of the present study is to determine the pharmacodynamics of H(2) in a model of isoproterenol (ISO)-induced cardiac hypertrophy. Methods: Mice (C57BL/6J; 8–10 weeks of age) were randomly assigned to four groups: Control group (n = 10), ISO group (n = 12), ISO plus H(2) group (n = 12), and H(2) group (n = 12). Mice received H(2) (1 ml/100g/day, intraperitoneal injection) for 7 days before ISO (0.5 mg/100g/day, subcutaneous injection) infusion, and then received ISO with or without H(2) for another 7 days. Then, cardiac function was evaluated by echocardiography. Cardiac hypertrophy was reflected by heart weight/body weight, gross morphology of hearts, and heart sections stained with hematoxylin and eosin, and relative atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) mRNA levels. Cardiac reactive oxygen species (ROS), 3-nitrotyrosine and p67 (phox) levels were analyzed by dihydroethidium staining, immunohistochemistry and Western blotting, respectively. For in vitro study, H9c2 cardiomyocytes were pretreated with H(2)-rich medium for 30 min, and then treated with ISO (10 μM) for the indicated time. The medium and ISO were re-changed every 24 h. Cardiomyocyte surface areas, relative ANP and BNP mRNA levels, the expression of 3-nitrotyrosine, and the dissipation of mitochondrial membrane potential (MMP) were examined. Moreover, the expression of extracellular signal-regulated kinase1/2 (ERK1/2), p-ERK1/2, p38, p-p38, c-Jun NH2-terminal kinase (JNK), and p-JNK were measured by Western blotting both in vivo and in vitro. Results: Intraperitoneal injection of H(2) prevented cardiac hypertrophy and improved cardiac function in ISO-infused mice. H(2)-rich medium blocked ISO-mediated cardiomyocytes hypertrophy in vitro. H(2) blocked the excessive expression of NADPH oxidase and the accumulation of ROS, attenuated the decrease of MMP, and inhibited ROS-sensitive ERK1/2, p38, and JNK signaling pathways. Conclusion: H(2) inhibits ISO-induced cardiac/cardiomyocytes hypertrophy both in vivo and in vitro, and improves the impaired left ventricular function. H(2) exerts its protective effects partially through blocking ROS-sensitive ERK1/2, p38, and JNK signaling pathways. Frontiers Media S.A. 2016-10-27 /pmc/articles/PMC5081383/ /pubmed/27833552 http://dx.doi.org/10.3389/fphar.2016.00392 Text en Copyright © 2016 Zhang, Xu, Long, Wang, Wang, Sun, Li and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Yaxing
Xu, Jingting
Long, Zhiyuan
Wang, Chen
Wang, Ling
Sun, Peng
Li, Ping
Wang, Tinghuai
Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
title Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
title_full Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
title_fullStr Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
title_full_unstemmed Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
title_short Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
title_sort hydrogen (h(2)) inhibits isoproterenol-induced cardiac hypertrophy via antioxidative pathways
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081383/
https://www.ncbi.nlm.nih.gov/pubmed/27833552
http://dx.doi.org/10.3389/fphar.2016.00392
work_keys_str_mv AT zhangyaxing hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways
AT xujingting hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways
AT longzhiyuan hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways
AT wangchen hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways
AT wangling hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways
AT sunpeng hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways
AT liping hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways
AT wangtinghuai hydrogenh2inhibitsisoproterenolinducedcardiachypertrophyviaantioxidativepathways